Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594165 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
A Phase 3 study of Early-Stage Parkinson's Disease, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
- 20
- Study locations
NCT00594165: Completed Phase 3 study of Early-Stage Parkinson's Disease, sponsored by UCB Pharma.
NCT00594165 is a Phase 3 study of Early-Stage Parkinson's Disease that has completed, run by UCB Pharma. The registered enrollment target is 217 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00594165, a Phase 3 study of Early-Stage Parkinson's Disease, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
Primary Outcome
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Conditions Studied
Interventions
- DRUG Rotigotine
Study Locations (20)
Arizona
- - Peoria
- - Phoenix
- - Tucson
California
- - Fountain Valley
- - Fresno
- - Los Angeles
Florida
- - Miami
- - Pompano Beach
- - Sunrise
Connecticut
- - Danbury
- - New Haven
Colorado
- - Englewood
Georgia
- - Atlanta
Illinois
- - Chicago
Indiana
- - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2002-06 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
What the finished NCT00594165 record still lists
NCT00594165 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Early-Stage Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Rotigotine is the first listed.
NCT00594165 names 20 study sites across 13 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00594165 about?
NCT00594165 is a clinical study titled "An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.". The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
What is the current status of trial NCT00594165?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2002-06. Estimated completion is 2008-11.
What conditions does trial NCT00594165 study?
This clinical trial studies the following conditions: Early-Stage Parkinson's Disease.
What interventions are being tested in trial NCT00594165?
The interventions under investigation include: Rotigotine (DRUG).
Who is sponsoring clinical trial NCT00594165?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00594165 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00594165's enrollment target sits among peer trials
217 1332nd of 2000 higher than 669 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia